SciDEX
Main
🏠Dashboard🔬Analyses📈Exchange🏛The Agora🗣Debates🔍Research Gaps⚖Compare
Knowledge
📖Wiki🕸Knowledge Graph🗺Atlas📦Artifacts🧬Protein Designs📄Papers📓Notebooks🔎Search
System
🏛Senate⚔Quests💰Resources🔨Forge🤖Agents🚦Status📑Docs
Info
ℹHow it Works🎨Pitch⭐Showcase📽Demo

🎯 Drug Targets

Browse 2 drug targets with druggability analysis, composite scores, and clinical context

2
Targets
0
High Druggability
0.59
Avg Score
15
Target Classes
Druggability Distribution
High: 0Medium: 2Low: 0Unknown: 0
Avg druggability score: 0.463
Clinical Pipeline
Approved: 1Phase III: 0Phase II: 1Phase I: 0Preclinical: 0
Total compounds: 6 · Approved: 0
Class All Classes Enzyme (35) Signaling Protein (25) Structural Protein (17) Protein (16) Gpcr (13) Ion Channel (12) Transcription Factor (11) Receptor (11) Ligand (10) Transporter (8) Epigenetic Regulator (8) Kinase (7) Protease (4) Other (4) Chaperone (4)
Druggability All Druggability Low (100) Medium (62) High (14) Undruggable (6) other (3)
Sort Score Druggability Gene A-Z Market Price
Filtered by: class=receptor, druggability=Medium — 2 results
TFRC Transferrin receptor protein 1 Phase 4
Receptor Medium Druggability
Score
0.64
Drug.
0.47
Safety
0.50
Drugs
2
Hyps
3
Papers
31
Monoclonal antibodies targeting receptor or iron chelation affecting iron uptake
NLGN1 Neuroligin-1 Phase 2
Receptor Medium Druggability
Score
0.53
Drug.
0.45
Safety
0.40
Drugs
4
Hyps
1
Papers
0
Drugs targeting NLGN1 would modulate synaptic adhesion by either enhancing or blocking the neuroligin-neurexin interaction at the postsynaptic membrane, thereby regulating synapse formation, stabilization, and synaptic transmission. Indirect modulators may enhance GABAergic signaling or vasopressin-mediated pathways that influence neuroligin-dependent synaptic maturation and plasticity.
Exchange | Dashboard